Vanessa Burrows Moderates FDLI Panel on Recent Rulings Surrounding Mifepristone Access
05.09.23
This is only gets display when printing
Healthcare Counsel Vanessa Burrows moderated a panel discussion titled “Recent Rulings on Mifepristone Access: Implications for FDA and Stakeholders” on May 4, which was hosted by the Food and Drug Law Institute (“FDLI”). She and the other panelists discussed Alliance for Hippocratic Medicine v. FDA, Washington v. FDA, and other recent federal court decisions concerning FDA approval of mifepristone and FDA Risk Evaluation and Mitigation Strategies (REMS). The speakers addressed the impact these decisions have on the medical community, along with broader implications for the FDA, investors, patients, and drug manufacturers around product approval.
For more information on the panel, please click here.